BJG-05-039
BJG-05-039 is a PAK1-selective degrader consisting of NVS-PAK1-1 conjugated to Lenalidomide (HY-A0003). BJG-05-039 induces selective degradation of PAK1. BJG-05-039 inhibits phosphorylation of MEK S298, as well as inhibiting phosphorylation of ERK. BJG-05-039 has an anti-proliferative effect on PAK1-dependent cell lines[1].
Product Specifications
CAS Number
3009849-06-0
UNSPSC
12352005
Target
MEK; PAK; PERK
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway
Field of Research
Cancer
Smiles
FC(F)CN1C2=C(C=C(Cl)C=C2)C(N[C@H]3CCN(C(NCCCCCCCCNC4=CC=CC(C(N5C6CCC(NC6=O)=O)=O)=C4C5=O)=O)C3)=NC7=CC(F)=CC=C17
Molecular Formula
C41H44ClF3N8O5
Molecular Weight
821.29
References & Citations
[1]Chow HY, et al. Development and Utility of a PAK1-Selective Degrader. J Med Chem. 2022 Dec 8;65 (23) :15627-15641.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![AF/LE Purified Anti-Human HLA-DR Antibody[L243]](https://cdn.genprice.uk/products/763/68dd14c4061270361e7d7114/imageurl/e-ab-f11110.webp)
AF/LE Purified Anti-Human HLA-DR Antibody[L243]
AF/LE Purified Anti-Human HLA-DR Antibody[L243]